BACKGROUND AND PURPOSE: Relative cerebral blood volume (rCBV) measurements derived from perfusion-weighted imaging (PWI) may be useful to evaluate angiogenesis and preoperatively estimate the grade of a glioma. We hypothesized that rCBV is correlated with vascular endothelial growth factor (VEGF) expression as marker of the angiogenic stimulus in presumed supratentorial low-grade gliomas (LGGs). METHODS: From February 2001 to February 2004, we examined 20 adults (16 men, four women; mean age 36 years; range, 23-60 years) with suspected (nonenhancing) supratentorial LGG on conventional MR imaging. Preoperative MR imaging used a dynamic first-pass gadolinium-enhanced, spin-echo echo-planar PWI. In heterogeneous tumors, we performed stereotactic biopsy in the high-perfusion areas before surgical resection. Semiquantitative grading of VEGF immunoreactivity was applied. RESULTS: Nine patients had diffuse astrocytomas (World Health Organization grade II), and 11 had other LGG and anaplastic gliomas. In patients with heterogeneous tumors on PWI, the high-rCBV focus had areas of oligodendroglioma or anaplastic astrocytoma on stereotactic biopsy, whereas the surgical specimens were predominantly astrocytomas. Anaplastic gliomas had high rCBV ratios and positive VEGF immunoreactivity. Diffuse astrocytomas had negative VEGF expression and mean rCBV values significantly lower than those of the other two groups. Three diffuse astrocytomas had positive VEGF immunoreactivity and high rCBV values. CONCLUSION: Our results confirmed the correlation among rCBV measurements, VEGF expression, and histopathologic grade in nonenhancing gliomas. PWI may add useful data to the preoperative assessment of nonenhancing gliomas. Its contribution in predicting tumor behavior and patient prognosis remains to be determined.
BACKGROUND AND PURPOSE: Relative cerebral blood volume (rCBV) measurements derived from perfusion-weighted imaging (PWI) may be useful to evaluate angiogenesis and preoperatively estimate the grade of a glioma. We hypothesized that rCBV is correlated with vascular endothelial growth factor (VEGF) expression as marker of the angiogenic stimulus in presumed supratentorial low-grade gliomas (LGGs). METHODS: From February 2001 to February 2004, we examined 20 adults (16 men, four women; mean age 36 years; range, 23-60 years) with suspected (nonenhancing) supratentorial LGG on conventional MR imaging. Preoperative MR imaging used a dynamic first-pass gadolinium-enhanced, spin-echo echo-planar PWI. In heterogeneous tumors, we performed stereotactic biopsy in the high-perfusion areas before surgical resection. Semiquantitative grading of VEGF immunoreactivity was applied. RESULTS: Nine patients had diffuse astrocytomas (World Health Organization grade II), and 11 had other LGG and anaplastic gliomas. In patients with heterogeneous tumors on PWI, the high-rCBV focus had areas of oligodendroglioma or anaplastic astrocytoma on stereotactic biopsy, whereas the surgical specimens were predominantly astrocytomas. Anaplastic gliomas had high rCBV ratios and positive VEGF immunoreactivity. Diffuse astrocytomas had negative VEGF expression and mean rCBV values significantly lower than those of the other two groups. Three diffuse astrocytomas had positive VEGF immunoreactivity and high rCBV values. CONCLUSION: Our results confirmed the correlation among rCBV measurements, VEGF expression, and histopathologic grade in nonenhancing gliomas. PWI may add useful data to the preoperative assessment of nonenhancing gliomas. Its contribution in predicting tumor behavior and patient prognosis remains to be determined.
Authors: Stephan G Wetzel; Soonmee Cha; Glyn Johnson; Peter Lee; Meng Law; David L Kasow; Sean D Pierce; Xiaonan Xue Journal: Radiology Date: 2002-09 Impact factor: 11.105
Authors: T Pietsch; M M Valter; H K Wolf; A von Deimling; H J Huang; W K Cavenee; O D Wiestler Journal: Acta Neuropathol Date: 1997-02 Impact factor: 17.088
Authors: F H Gilles; W D Brown; A Leviton; C J Tavaré; L Adelman; L B Rorke; R L Davis; T E Hedley-Whyte Journal: Cancer Date: 2000-03-15 Impact factor: 6.860
Authors: K M Donahue; H G Krouwer; S D Rand; A P Pathak; C S Marszalkowski; S C Censky; R W Prost Journal: Magn Reson Med Date: 2000-06 Impact factor: 4.668
Authors: S J Lee; J H Kim; Y M Kim; G K Lee; E J Lee; I S Park; J M Jung; K H Kang; T Shin Journal: Korean J Radiol Date: 2001 Jan-Mar Impact factor: 3.500
Authors: D Frappaz; O Chinot; A Bataillard; M Ben Hassel; L Capelle; S Chanalet; M Chatel; D Figarella-Branger; Y Guegan; J Guyotat; K Hoang-Xuan; E Jouanneau; F Keime-Guibert; C Laforêt; C Linassier; H Loiseau; J P Maire; P Menei; S Rousmans; M Sanson; M P Sunyach Journal: Br J Cancer Date: 2003-08 Impact factor: 7.640
Authors: R Jain; J Gutierrez; J Narang; L Scarpace; L R Schultz; N Lemke; S C Patel; T Mikkelsen; J P Rock Journal: AJNR Am J Neuroradiol Date: 2010-11-11 Impact factor: 3.825
Authors: Ana C Pereira; Dan E Huddleston; Adam M Brickman; Alexander A Sosunov; Rene Hen; Guy M McKhann; Richard Sloan; Fred H Gage; Truman R Brown; Scott A Small Journal: Proc Natl Acad Sci U S A Date: 2007-03-20 Impact factor: 11.205
Authors: Ramon F Barajas; Jamie S Chang; Mark R Segal; Andrew T Parsa; Michael W McDermott; Mitchel S Berger; Soonmee Cha Journal: Radiology Date: 2009-09-29 Impact factor: 11.105
Authors: Rajiv Mangla; Daniel Thomas Ginat; Shervin Kamalian; Michael T Milano; David N Korones; Kevin A Walter; Sven Ekholm Journal: J Neurooncol Date: 2013-11-01 Impact factor: 4.130
Authors: A Romano; M C Rossi Espagnet; L F Calabria; V Coppola; L Figà Talamanca; V Cipriani; G Minniti; A Pierallini; L M Fantozzi; A Bozzao Journal: Radiol Med Date: 2011-09-02 Impact factor: 3.469
Authors: R Jain; S K Ellika; L Scarpace; L R Schultz; J P Rock; J Gutierrez; S C Patel; J Ewing; T Mikkelsen Journal: AJNR Am J Neuroradiol Date: 2008-01-17 Impact factor: 3.825